Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Altering cellular reducing potential changes 64Cu-ATSM signal with or without hypoxia.

Floberg JM, Wang L, Bandara N, Rashmi R, Mpoy C, Garbow JR, Rogers BE, Patti GJ, Schwarz JK.

J Nucl Med. 2019 Oct 4. pii: jnumed.119.230805. doi: 10.2967/jnumed.119.230805. [Epub ahead of print]

PMID:
31586008
2.

Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.

Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL.

Am J Clin Oncol. 2019 Oct;42(10):755-760. doi: 10.1097/COC.0000000000000599.

PMID:
31513018
3.

Neutrophils promote tumor resistance to radiation therapy.

Wisdom AJ, Hong CS, Lin AJ, Xiang Y, Cooper DE, Zhang J, Xu ES, Kuo HC, Mowery YM, Carpenter DJ, Kadakia KT, Himes JE, Luo L, Ma Y, Williams N, Cardona DM, Haldar M, Diao Y, Markovina S, Schwarz JK, Kirsch DG.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18584-18589. doi: 10.1073/pnas.1901562116. Epub 2019 Aug 28.

PMID:
31462499
4.

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

PMID:
31270275
5.

MRI safety risks in the obese: The case of the disposable lighter stored in the pannus.

Gach HM, Mackey SL, Hausman SE, Jackson DR, Benzinger TL, Henke L, Murphy LA, Fluchel JL, Cai B, Zoberi JE, Garcia-Ramirez J, Mutic S, Schwarz JK.

Radiol Case Rep. 2019 Mar 15;14(5):634-638. doi: 10.1016/j.radcr.2019.02.023. eCollection 2019 May.

6.

Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.

Lin C, Verma V, Ly QP, Lazenby A, Sasson A, Schwarz JK, Meza JL, Are C, Li S, Wang S, Hahn SM, Grem JL.

Radiother Oncol. 2019 Mar;132:55-62. doi: 10.1016/j.radonc.2018.11.002. Epub 2018 Dec 20.

PMID:
30825970
7.

Manipulation of Glucose and Hydroperoxide Metabolism to Improve Radiation Response.

Floberg JM, Schwarz JK.

Semin Radiat Oncol. 2019 Jan;29(1):33-41. doi: 10.1016/j.semradonc.2018.10.007. Review.

8.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

9.

Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer.

Floberg JM, Fowler KJ, Fuser D, DeWees TA, Dehdashti F, Siegel BA, Wahl RL, Schwarz JK, Grigsby PW.

EJNMMI Res. 2018 Jun 15;8(1):52. doi: 10.1186/s13550-018-0403-7.

10.

Assisted Suicide/Aid in Dying: What Is the Nurse's Role?

Hamric AB, Schwarz JK, Cohen L, Mahon M.

Am J Nurs. 2018 May;118(5):50-59. doi: 10.1097/01.NAJ.0000532831.78142.40.

PMID:
29698279
11.

Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.

Grigsby P, Elhammali A, Ruiz F, Markovina S, McLellan MD, Miller CA, Chundury A, Ta NL, Rashmi R, Pfeifer JD, Fulton RS, DeWees T, Schwarz JK.

Oncotarget. 2017 Dec 23;9(3):4061-4073. doi: 10.18632/oncotarget.23664. eCollection 2018 Jan 9.

12.

Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.

Rashmi R, Huang X, Floberg JM, Elhammali AE, McCormick ML, Patti GJ, Spitz DR, Schwarz JK.

Cancer Res. 2018 Mar 15;78(6):1392-1403. doi: 10.1158/0008-5472.CAN-17-2367. Epub 2018 Jan 16.

13.

Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis.

Rao YJ, Sein J, Badiyan S, Schwarz JK, DeWees T, Grigsby P, Rao PK.

J Contemp Brachytherapy. 2017 Oct;9(5):453-465. doi: 10.5114/jcb.2017.70986. Epub 2017 Oct 20.

14.

The Future of Radiobiology.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ.

J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. doi: 10.1093/jnci/djx231.

15.

Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.

Markovina S, Wang S, Henke LE, Luke CJ, Pak SC, DeWees T, Pfeifer JD, Schwarz JK, Liu W, Chen S, Mutch D, Wang X, Powell MA, Siegel BA, Dehdashti F, Silverman GA, Grigsby PW.

Br J Cancer. 2018 Jan;118(1):72-78. doi: 10.1038/bjc.2017.390. Epub 2017 Nov 7.

16.

Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes.

Rao YJ, Chundury A, Schwarz JK, Hassanzadeh C, DeWees T, Mullen D, Powell MA, Mutch DG, Grigsby PW.

Adv Radiat Oncol. 2017 Feb 28;2(2):148-158. doi: 10.1016/j.adro.2017.02.006. eCollection 2017 Apr-Jun.

17.

Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.

Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, Grigsby PW, Markovina S.

Gynecol Oncol. 2017 Sep;146(3):572-579. doi: 10.1016/j.ygyno.2017.06.022. Epub 2017 Jun 27.

PMID:
28662775
18.

Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis.

Rao YJ, Hui C, Chundury A, Schwarz JK, DeWees T, Powell MA, Mutch DG, Grigsby PW.

Brachytherapy. 2017 Jul - Aug;16(4):831-840. doi: 10.1016/j.brachy.2017.03.012. Epub 2017 May 19.

PMID:
28533162
19.

Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment.

Ioffe YJ, Massad LS, Powell MA, Hagemann AR, Mutch DG, Thaker PH, Schwarz JK, Grigsby PW.

Gynecol Obstet Invest. 2018;83(1):83-89. doi: 10.1159/000458706. Epub 2017 Apr 8.

PMID:
28399524
20.

Metal artifact reduction in MRI-based cervical cancer intracavitary brachytherapy.

Rao YJ, Zoberi JE, Kadbi M, Grigsby PW, Cammin J, Mackey SL, Garcia-Ramirez J, Goddu SM, Schwarz JK, Gach HM.

Phys Med Biol. 2017 Apr 21;62(8):3011-3024. doi: 10.1088/1361-6560/62/8/3011. Epub 2017 Mar 17.

PMID:
28306556
21.

Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva.

Rao YJ, Hassanzadeh C, Chundury A, Hui C, Siegel BA, Dehdashti F, DeWees T, Mullen D, Powell MA, Mutch DG, Schwarz JK, Grigsby PW.

Radiother Oncol. 2017 Mar;122(3):445-451. doi: 10.1016/j.radonc.2016.12.019. Epub 2017 Jan 4.

PMID:
28063696
22.

Sarah's Second Attempt to Stop Eating and Drinking: Success at Last.

Schwarz JK.

Narrat Inq Bioeth. 2016;6(2):99-101. No abstract available.

PMID:
27763396
23.

Drug Delivery Approaches for the Treatment of Cervical Cancer.

Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK.

Pharmaceutics. 2016 Jul 20;8(3). pii: E23. doi: 10.3390/pharmaceutics8030023. Review.

24.

Clinical implementation of multisequence MRI-based adaptive intracavitary brachytherapy for cervix cancer.

Zoberi JE, Garcia-Ramirez J, Hu Y, Sun B, Bertelsman CG, Dyk P, Schwarz JK, Grigsby PW.

J Appl Clin Med Phys. 2016 Jan 8;17(1):121-131. doi: 10.1120/jacmp.v17i1.5736.

25.

Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.

Chundury A, Apicelli A, DeWees T, Powell M, Mutch D, Thaker P, Robinson C, Grigsby PW, Schwarz JK.

Gynecol Oncol. 2016 Apr;141(1):134-9. doi: 10.1016/j.ygyno.2016.02.005. Epub 2016 Feb 10.

PMID:
26876923
26.

Medically inoperable endometrial cancer in patients with a high body mass index (BMI): Patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy.

Acharya S, Esthappan J, Badiyan S, DeWees TA, Tanderup K, Schwarz JK, Grigsby PW.

Radiother Oncol. 2016 Jan;118(1):167-72. doi: 10.1016/j.radonc.2015.12.019. Epub 2015 Dec 29.

PMID:
26743834
27.

An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive summary.

Jones E, Beriwal S, Beyer D, Chino J, Jhingran A, Lee L, Michalski J, Mundt AJ, Patton C, Petersen I, Portelance L, Schwarz JK, McCloskey S.

Adv Radiat Oncol. 2015 Dec 17;1(1):26-34. doi: 10.1016/j.adro.2015.10.001. eCollection 2016 Jan-Mar.

28.
29.

Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.

Acharya S, Perkins SM, DeWees T, Fischer-Valuck BW, Mutch DG, Powell MA, Schwarz JK, Grigsby PW.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):649-57. doi: 10.1016/j.ijrobp.2015.06.013. Epub 2015 Jun 15.

PMID:
26461007
30.

A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.

Grem JL, Kos ME, Evande RE, Meza JL, Schwarz JK.

Cancer. 2015 Nov 1;121(21):3862-8. doi: 10.1002/cncr.29504. Epub 2015 Aug 4.

31.

Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer.

Schwarz JK, Beriwal S, Esthappan J, Erickson B, Feltmate C, Fyles A, Gaffney D, Jones E, Klopp A, Small W Jr, Thomadsen B, Yashar C, Viswanathan A.

Brachytherapy. 2015 Sep-Oct;14(5):587-99. doi: 10.1016/j.brachy.2015.06.002. Epub 2015 Jul 15.

PMID:
26186975
32.

PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer.

Bagade S, Fowler KJ, Schwarz JK, Grigsby PW, Dehdashti F.

Semin Nucl Med. 2015 Jul;45(4):293-303. doi: 10.1053/j.semnuclmed.2015.03.005. Review.

PMID:
26050657
33.

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.

Giri S, Hamdeh S, Bhatt VR, Schwarz JK.

J Natl Compr Canc Netw. 2015 May;13(5):508-14.

PMID:
25964636
34.

Three-dimensional dose accumulation in pseudo-split-field IMRT and brachytherapy for locally advanced cervical cancer.

Sun B, Yang D, Esthappan J, Garcia-Ramirez J, Price S, Mutic S, Schwarz JK, Grigsby PW, Tanderup K.

Brachytherapy. 2015 Jul-Aug;14(4):481-9. doi: 10.1016/j.brachy.2015.04.003. Epub 2015 May 6.

PMID:
25958039
35.

Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?

Paydar I, DeWees T, Powell M, Mutch DG, Grigsby PW, Schwarz JK.

Brachytherapy. 2015 Jul-Aug;14(4):427-32. doi: 10.1016/j.brachy.2015.02.196. Epub 2015 Apr 22.

PMID:
25911995
36.

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.

Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, El-Mofty S, Moley JF, Nussenbaum B, Haughey BH, Baranski TJ, Schwarz JK, Grigsby PW.

Cancer Med. 2015 Jun;4(6):791-9. doi: 10.1002/cam4.417. Epub 2015 Feb 25.

37.

Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Wang J, McGuire TR, Britton HC, Schwarz JK, Loberiza FR Jr, Meza JL, Talmadge JE.

Clin Exp Metastasis. 2015 Feb;32(2):111-24. doi: 10.1007/s10585-015-9696-3. Epub 2015 Jan 25.

PMID:
25617965
38.

Outpatient-based high-dose-rate interstitial brachytherapy for gynecologic malignancies.

Dyk PT, Richardson S, Badiyan SN, Schwarz JK, Esthappan J, Garcia-Ramirez JL, Grigsby PW.

Brachytherapy. 2015 Mar-Apr;14(2):231-7. doi: 10.1016/j.brachy.2014.11.017. Epub 2015 Jan 1.

PMID:
25556865
39.

Activation of miR-9 by human papillomavirus in cervical cancer.

Liu W, Gao G, Hu X, Wang Y, Schwarz JK, Chen JJ, Grigsby PW, Wang X.

Oncotarget. 2014 Nov 30;5(22):11620-30.

40.

Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy.

Dyk P, Jiang N, Sun B, DeWees TA, Fowler KJ, Narra V, Garcia-Ramirez JL, Schwarz JK, Grigsby PW.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):794-801. doi: 10.1016/j.ijrobp.2014.07.039. Epub 2014 Sep 20.

PMID:
25245584
41.

Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.

Bhatt VR, Ganti AK, Schwarz JK, Wang J.

Future Oncol. 2014 Apr;10(5):703-6. doi: 10.2217/fon.14.5. No abstract available.

PMID:
24799051
42.

Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence.

Markovina S, Grigsby PW, Schwarz JK, DeWees T, Moley JF, Siegel BA, Perkins SM.

Thyroid. 2014 Jul;24(7):1121-6. doi: 10.1089/thy.2013.0297. Epub 2014 May 28.

PMID:
24731094
43.

AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.

Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW, Schwarz JK.

PLoS One. 2014 Apr 4;9(4):e92948. doi: 10.1371/journal.pone.0092948. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107846. Rader, Janet [corrected to Rader, Janet L].

44.

Postradiation damage to the pelvic girdle in cervical cancer patients: is intensity-modulated radiation therapy safer than conventional radiation?

Ioffe YJ, Hillen TJ, Zhou G, Schwarz JK, Massad LS, Powell MA, Hagemann AR, Mutch DG, Thaker PH.

Int J Gynecol Cancer. 2014 May;24(4):806-12. doi: 10.1097/IGC.0000000000000117.

PMID:
24670967
45.

Translating imaging results into tumor biology: FDG-PET and the response to chemoradiation in human cervical carcinoma.

Schwarz JK.

Radiat Res. 2013 Sep;180(3):223-30. doi: 10.1667/RR3392.1. Epub 2013 Jul 30.

PMID:
23899375
46.

In vitro chemoresponse to cisplatin and outcomes in cervical cancer.

Grigsby PW, Zighelboim I, Powell MA, Mutch DG, Schwarz JK.

Gynecol Oncol. 2013 Jul;130(1):188-91. doi: 10.1016/j.ygyno.2013.04.005. Epub 2013 Apr 10.

47.

Improve definition of titanium tandems in MR-guided high dose rate brachytherapy for cervical cancer using proton density weighted MRI.

Hu Y, Esthappan J, Mutic S, Richardson S, Gay HA, Schwarz JK, Grigsby PW.

Radiat Oncol. 2013 Jan 17;8:16. doi: 10.1186/1748-717X-8-16.

48.

Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix.

Olsen JR, Esthappan J, DeWees T, Narra VR, Dehdashti F, Siegel BA, Schwarz JK, Grigsby PW.

J Magn Reson Imaging. 2013 Feb;37(2):431-4. doi: 10.1002/jmri.23830. Epub 2012 Sep 28.

49.

Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.

Shokeen M, Zheleznyak A, Wilson JM, Jiang M, Liu R, Ferdani R, Lam KS, Schwarz JK, Anderson CJ.

J Nucl Med. 2012 May;53(5):779-86. doi: 10.2967/jnumed.111.100073. Epub 2012 Apr 10.

50.

Prognostic significance of p16 expression in advanced cervical cancer treated with definitive radiotherapy.

Schwarz JK, Lewis JS Jr, Pfeifer J, Huettner P, Grigsby P.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):153-7. doi: 10.1016/j.ijrobp.2011.11.032. Epub 2012 Feb 11.

PMID:
22330994

Supplemental Content

Loading ...
Support Center